Fingolimod Norameda 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

fingolimod norameda 0,5 mg cietās kapsulas

norameda uab, lithuania - fingolimods - kapsula, cietā - 0,5 mg

Chantico 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

chantico 0,5 mg cietās kapsulas

g.l. pharma gmbh, austria - fingolimods - kapsula, cietā - 0,5 mg

Fingolimod Accord Union européenne - letton - EMA (European Medicines Agency)

fingolimod accord

accord healthcare s.l.u. - fingolimod hidrohlorīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - norāda kā vienu slimību modificējošiem terapija ir ļoti aktīvs recidivējoši pārskaitot multiplo sklerozi, par šādu grupu pieaugušiem pacientiem un pediatrijas pacienti vecumā no 10 gadiem un vecāki:pacientiem ar ļoti aktīvu slimību, neskatoties uz pilnu un atbilstošu ārstēšanas kursu, ar vismaz vienu slimību modificējošiem therapyorpatients strauji attīstās smagas recidivējoši pārskaitot multiplā skleroze definēts 2 vai vairāk atspējošana recidīvu vienu gadu, un ar 1 vai vairāk gadolīnija uzlabot bojājumi uz smadzeņu mri vai ievērojami palielināt t2 bojājumu slodzes salīdzinājumā ar iepriekšējā pēdējo mr.

Fingolimod Grindeks 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

fingolimod grindeks 0,5 mg cietās kapsulas

grindeks, as, latvia - fingolimods - kapsula, cietā - 0,5 mg

Fingolimod Zentiva 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

fingolimod zentiva 0,5 mg cietās kapsulas

zentiva, k.s., czech republic - fingolimods - kapsula, cietā - 0,5 mg

Fingolimod Medochemie 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

fingolimod medochemie 0,5 mg cietās kapsulas

medochemie ltd., cyprus - fingolimods - kapsula, cietā - 0,5 mg

Fingolimod Teva 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

fingolimod teva 0,5 mg cietās kapsulas

teva gmbh, germany - fingolimods - kapsula, cietā - 0,5 mg

Efigalo 0,5 mg cietās kapsulas Lettonie - letton - Zāļu valsts aģentūra

efigalo 0,5 mg cietās kapsulas

krka, d.d., novo mesto, slovenia - fingolimods - kapsula, cietā - 0,5 mg

Jayempi Union européenne - letton - EMA (European Medicines Agency)

jayempi

nova laboratories ireland limited - azatioprīns - transplanta noraidīšana - imūnsupresanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Ponvory Union européenne - letton - EMA (European Medicines Agency)

ponvory

janssen-cilag international n.v.    - ponesimod - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.